UPLOAD Filing
Silexion Therapeutics Corp
Date: April 28, 2025 · CIK: 0002022416 · Accession: 0000000000-25-004487
AI Filing Summary & Sentiment
Reasoning
Letter
April 28, 2025 Ilan Hadar Chairman and Chief Executive Officer Silexion Therapeutics Corp 12 Abba Hillel Road Ramat Gan, Israel 5250606 Re:Silexion Therapeutics Corp Draft Registration Statement on Form S-1 Filed April 23, 2025 File No. 377-07931 Dear Ilan Hadar: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary M. Emmanuel, Esq.
Show Raw Text
April 28, 2025
Ilan Hadar
Chairman and Chief Executive Officer
Silexion Therapeutics Corp
12 Abba Hillel Road
Ramat Gan, Israel 5250606
Re:Silexion Therapeutics Corp
Draft Registration Statement on Form S-1
Filed April 23, 2025
File No. 377-07931
Dear Ilan Hadar:
This is to advise you that we do not intend to review your registration statement.
We request that you publicly file your registration statement at least two business
days prior to the requested effective date and time. Please refer to Rules 460 and 461
regarding requests for acceleration. We remind you that the company and its management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary M. Emmanuel, Esq.